Q11306 (Q11306): Difference between revisions
Jump to navigation
Jump to search
(Removed claims) |
(Changed an Item) |
||||||||||||||
| Property / EU contribution | |||||||||||||||
29,985,600.0 Czech koruna
| |||||||||||||||
| Property / EU contribution: 29,985,600.0 Czech koruna / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / EU contribution | |||||||||||||||
1,199,424.0 Euro
| |||||||||||||||
| Property / EU contribution: 1,199,424.0 Euro / rank | |||||||||||||||
Preferred rank | |||||||||||||||
| Property / EU contribution: 1,199,424.0 Euro / qualifier | |||||||||||||||
exchange rate to Euro: 0.04 Euro
| |||||||||||||||
| Property / EU contribution: 1,199,424.0 Euro / qualifier | |||||||||||||||
point in time: 10 January 2020
| |||||||||||||||
| Property / budget | |||||||||||||||
48,000,000.0 Czech koruna
| |||||||||||||||
| Property / budget: 48,000,000.0 Czech koruna / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / budget | |||||||||||||||
1,920,000.0 Euro
| |||||||||||||||
| Property / budget: 1,920,000.0 Euro / rank | |||||||||||||||
Preferred rank | |||||||||||||||
| Property / budget: 1,920,000.0 Euro / qualifier | |||||||||||||||
exchange rate to Euro: 0.04 Euro
| |||||||||||||||
| Property / budget: 1,920,000.0 Euro / qualifier | |||||||||||||||
point in time: 10 January 2020
| |||||||||||||||
Revision as of 00:34, 12 February 2020
Project in Czech Republic financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project in Czech Republic financed by DG Regio |
Statements
29,985,600.0 Czech koruna
0 references
48,000,000.0 Czech koruna
0 references
62.47 percent
0 references
1 January 2018
0 references
19 April 2020
0 references
Institute of Applied Biotechnologies a.s.
0 references
50°5'1.93"N, 14°30'28.48"E
0 references
10800
0 references
Jedná se o multidisciplinární vysoce inovativní projekt zaměřený na vývoj diagnostických souprav pro detekci klinicky relevantních mutací u chronické lymfocytární leukemie a mnohočetného myelomu, včetně vývoje vyhodnocovacího softwaru pro klinické vyhodnocení mutací. Cílem tohoto průmyslového vývoje a výzkumu je produkt vysoké míry specifičnosti a inovativnosti využívající techniku sekvenování nové generace s vlastnostmi, které současný trh nenabízí. a. (Czech)
0 references
Identifiers
CZ.01.1.02/0.0/0.0/16_084/0010310
0 references